RODMAN&RENSHAW Upgrades Atara Biotherapeutics (NASDAQ:ATRA) to "Strong-Buy"

RODMAN&RENSHAW upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA - Free Report) to a strong-buy rating in a research note issued to investors on Friday,Zacks.com reports.

Other equities research analysts have also issued reports about the company. Canaccord Genuity Group lifted their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. TD Cowen upgraded shares of Atara Biotherapeutics to a "strong-buy" rating in a research note on Friday, November 29th. Finally, Rodman & Renshaw began coverage on shares of Atara Biotherapeutics in a research note on Friday. They set a "buy" rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $18.75.

Atara Biotherapeutics Price Performance

Atara Biotherapeutics stock traded up $1.47 during trading hours on Friday, hitting $11.40. The company had a trading volume of 152,253 shares, compared to its average volume of 104,916. Atara Biotherapeutics has a fifty-two week low of $6.50 and a fifty-two week high of $39.50. The firm has a market capitalization of $65.66 million, a P/E ratio of -0.44 and a beta of 0.55. The firm's fifty day moving average is $10.80 and its 200-day moving average is $9.60.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping analysts' consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same period last year, the company posted ($16.50) earnings per share. Analysts anticipate that Atara Biotherapeutics will post -12.12 earnings per share for the current year.

Hedge Funds Weigh In On Atara Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Atara Biotherapeutics during the 2nd quarter worth $53,000. Cubist Systematic Strategies LLC acquired a new position in Atara Biotherapeutics during the 2nd quarter worth $79,000. State Street Corp boosted its holdings in Atara Biotherapeutics by 52.3% during the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company's stock valued at $182,000 after acquiring an additional 7,680 shares during the period. FMR LLC grew its position in shares of Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company's stock valued at $204,000 after purchasing an additional 7,381 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Atara Biotherapeutics by 9.5% in the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company's stock valued at $380,000 after purchasing an additional 4,043 shares during the last quarter. Institutional investors and hedge funds own 70.90% of the company's stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.